vs
Side-by-side financial comparison of CorMedix Inc. (CRMD) and LiveRamp Holdings, Inc. (RAMP). Click either name above to swap in a different company.
LiveRamp Holdings, Inc. is the larger business by last-quarter revenue ($212.2M vs $128.6M, roughly 1.6× CorMedix Inc.).
CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutic products for the prevention and treatment of infectious, inflammatory and cardiorenal diseases. Its lead candidate targets catheter-related bloodstream infections, serving critical care and chronic dialysis patient populations primarily across North America and European markets.
LiveRamp Holdings, Inc., is an American SaaS company that offers a data connectivity platform whose services include data onboarding, the transfer of offline data online for marketing purposes.
CRMD vs RAMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $128.6M | $212.2M |
| Net Profit | — | $39.9M |
| Gross Margin | 83.4% | 71.9% |
| Operating Margin | 46.0% | 18.6% |
| Net Margin | — | 18.8% |
| Revenue YoY | — | 8.6% |
| Net Profit YoY | — | 255.7% |
| EPS (diluted) | $0.20 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $128.6M | $212.2M | ||
| Q3 25 | $104.3M | $199.8M | ||
| Q2 25 | $39.7M | $194.8M | ||
| Q1 25 | $39.1M | $188.7M | ||
| Q4 24 | — | $195.4M | ||
| Q3 24 | — | $185.5M | ||
| Q2 24 | — | $176.0M | ||
| Q1 24 | — | $171.9M |
| Q4 25 | — | $39.9M | ||
| Q3 25 | $108.6M | $27.4M | ||
| Q2 25 | $19.8M | $7.7M | ||
| Q1 25 | $20.6M | $-6.3M | ||
| Q4 24 | — | $11.2M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $-7.5M | ||
| Q1 24 | — | $-5.4M |
| Q4 25 | 83.4% | 71.9% | ||
| Q3 25 | 89.3% | 70.2% | ||
| Q2 25 | 95.3% | 70.1% | ||
| Q1 25 | 95.9% | 69.3% | ||
| Q4 24 | — | 71.9% | ||
| Q3 24 | — | 72.4% | ||
| Q2 24 | — | 70.6% | ||
| Q1 24 | — | 72.2% |
| Q4 25 | 46.0% | 18.6% | ||
| Q3 25 | 49.2% | 10.7% | ||
| Q2 25 | 49.2% | 3.7% | ||
| Q1 25 | 51.5% | -6.1% | ||
| Q4 24 | — | 7.5% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | — | -3.0% | ||
| Q1 24 | — | -8.3% |
| Q4 25 | — | 18.8% | ||
| Q3 25 | 104.1% | 13.7% | ||
| Q2 25 | 49.9% | 4.0% | ||
| Q1 25 | 52.8% | -3.3% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | -4.3% | ||
| Q1 24 | — | -3.1% |
| Q4 25 | $0.20 | $0.62 | ||
| Q3 25 | $1.26 | $0.42 | ||
| Q2 25 | $0.28 | $0.12 | ||
| Q1 25 | $0.30 | $-0.10 | ||
| Q4 24 | — | $0.17 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | — | $-0.11 | ||
| Q1 24 | — | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $148.5M | $403.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $405.3M | $962.3M |
| Total Assets | $826.1M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $148.5M | $403.4M | ||
| Q3 25 | $55.7M | $376.9M | ||
| Q2 25 | $190.7M | $371.1M | ||
| Q1 25 | $77.5M | $420.8M | ||
| Q4 24 | — | $384.3M | ||
| Q3 24 | — | $348.4M | ||
| Q2 24 | — | $342.7M | ||
| Q1 24 | — | $368.9M |
| Q4 25 | $405.3M | $962.3M | ||
| Q3 25 | $374.1M | $943.8M | ||
| Q2 25 | $220.6M | $947.8M | ||
| Q1 25 | $114.9M | $948.9M | ||
| Q4 24 | — | $957.7M | ||
| Q3 24 | — | $932.1M | ||
| Q2 24 | — | $951.9M | ||
| Q1 24 | — | $949.1M |
| Q4 25 | $826.1M | $1.3B | ||
| Q3 25 | $750.9M | $1.2B | ||
| Q2 25 | $252.6M | $1.2B | ||
| Q1 25 | $149.6M | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $94.5M | — |
| Free Cash FlowOCF − Capex | $92.7M | — |
| FCF MarginFCF / Revenue | 72.1% | — |
| Capex IntensityCapex / Revenue | 1.3% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $172.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $94.5M | — | ||
| Q3 25 | $30.9M | $57.4M | ||
| Q2 25 | $30.0M | $-15.8M | ||
| Q1 25 | $19.7M | — | ||
| Q4 24 | — | $45.1M | ||
| Q3 24 | — | $55.6M | ||
| Q2 24 | — | $-9.3M | ||
| Q1 24 | — | — |
| Q4 25 | $92.7M | — | ||
| Q3 25 | $30.4M | $56.8M | ||
| Q2 25 | $30.0M | $-16.2M | ||
| Q1 25 | $19.7M | — | ||
| Q4 24 | — | $44.8M | ||
| Q3 24 | — | $55.4M | ||
| Q2 24 | — | $-9.6M | ||
| Q1 24 | — | — |
| Q4 25 | 72.1% | — | ||
| Q3 25 | 29.1% | 28.4% | ||
| Q2 25 | 75.4% | -8.3% | ||
| Q1 25 | 50.5% | — | ||
| Q4 24 | — | 22.9% | ||
| Q3 24 | — | 29.8% | ||
| Q2 24 | — | -5.4% | ||
| Q1 24 | — | — |
| Q4 25 | 1.3% | 0.1% | ||
| Q3 25 | 0.5% | 0.3% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 0.0% | 0.2% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | 0.28× | 2.09× | ||
| Q2 25 | 1.51× | -2.04× | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | 4.02× | ||
| Q3 24 | — | 32.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
RAMP
Segment breakdown not available.
